Belite Bio (BLTE) Net Income towards Common Stockholders (2022 - 2026)

Belite Bio's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$0.68 for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 251.11% year-over-year to -$0.68 in Q1 2026; TTM through Mar 2026 was $0.17, a 77.03% decrease from a year earlier, with the FY2025 full-year figure at $2.31, up 95.76% from the prior year.
• Net Income towards Common Stockholders declined to -$0.68 in Q1 2026 per BLTE's latest filing, from $0.7 in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $0.7 in Q4 2025 and bottomed at -$0.68 in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is $0.27 (2022), against an average of $0.12.
• Biggest YoY gain for Net Income towards Common Stockholders was 300.0% in 2023; the steepest drop was 316.67% in 2023.
• Year by year, Net Income towards Common Stockholders stood at $0.27 in 2022, then slumped by 192.59% to -$0.25 in 2023, then jumped by 228.0% to $0.32 in 2024, then jumped by 118.75% to $0.7 in 2025, then tumbled by 197.14% to -$0.68 in 2026.
• Per Business Quant, the three latest BLTE Net Income towards Common Stockholders figures stand at -$0.68 (Q1 2026), $0.7 (Q4 2025), and $0.65 (Q3 2025).